Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Annaberdyev, Shohrat, Gibbons, Joseph, Hardacre, Jeffrey M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661077/
https://www.ncbi.nlm.nih.gov/pubmed/19291285
http://dx.doi.org/10.1186/1477-7819-7-30
_version_ 1782165782814261248
author Annaberdyev, Shohrat
Gibbons, Joseph
Hardacre, Jeffrey M
author_facet Annaberdyev, Shohrat
Gibbons, Joseph
Hardacre, Jeffrey M
author_sort Annaberdyev, Shohrat
collection PubMed
description Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.
format Text
id pubmed-2661077
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26610772009-03-26 Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy Annaberdyev, Shohrat Gibbons, Joseph Hardacre, Jeffrey M World J Surg Oncol Case Report Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection. BioMed Central 2009-03-16 /pmc/articles/PMC2661077/ /pubmed/19291285 http://dx.doi.org/10.1186/1477-7819-7-30 Text en Copyright © 2009 Annaberdyev et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Annaberdyev, Shohrat
Gibbons, Joseph
Hardacre, Jeffrey M
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title_full Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title_fullStr Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title_full_unstemmed Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title_short Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
title_sort dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661077/
https://www.ncbi.nlm.nih.gov/pubmed/19291285
http://dx.doi.org/10.1186/1477-7819-7-30
work_keys_str_mv AT annaberdyevshohrat dramaticresponseofagastrointestinalstromaltumortoneadjuvantimatinibtherapy
AT gibbonsjoseph dramaticresponseofagastrointestinalstromaltumortoneadjuvantimatinibtherapy
AT hardacrejeffreym dramaticresponseofagastrointestinalstromaltumortoneadjuvantimatinibtherapy

Ejemplares similares